Mydecine Innovations Group Stock Price, News & Analysis

MYCOF OTC Link

Company Description

Mydecine Innovations Group Inc. is a forefront biotechnology company focused on revolutionizing mental health and addiction treatment. They have received a Notice of Allowance from the USPTO for their MYCO-005 compound, a novel psilocin analog engineered to reduce side effects and address valvular fibrosis concerns. This breakthrough compound, with selective binding to 5-HT2A receptors, offers potential heart-safe microdose-enabling properties, making it a safer alternative for those suffering from anxiety or depression disorders.

The company is dedicated to pioneering safer and more effective solutions for mental health and addiction disorders, emphasizing innovation and research in the field of biotechnology. They provide turnkey growing infrastructure and services for licensed growers and processors of marijuana crops to support the farming industry, showcasing a commitment to advancing agriculture and biotechnological advancements.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$247.5K

Market Cap

61.8M

Shares outstanding

Latest News

View All

December 18, 2023

44.46%

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

October 26, 2023

3.69%

Mydecine Provides Q4 2023 Business Update

earnings

October 12, 2023

3.03%

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

October 10, 2023

43.91%

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

August 30, 2023

0.18%

Mydecine Announces Conditional Approval of CSE Listing

May 29, 2023

13.63%

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors

management

SEC Filings

View All

No SEC filings available for Mydecine Innovations Group.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Loading short interest data...

Days to Cover History

Last 12 Months

Loading days to cover data...

Frequently Asked Questions

What is the current stock price of Mydecine Innovations Group (MYCOF)?

The current stock price of Mydecine Innovations Group (MYCOF) is $0.00648 as of September 24, 2025.

What is the market cap of Mydecine Innovations Group (MYCOF)?

The market cap of Mydecine Innovations Group (MYCOF) is approximately 247.5K. Learn more about what market capitalization means .

What is MYCO-005?

MYCO-005 is a novel psilocin analog developed by Mydecine Innovations Group Inc. with selective binding to 5-HT2A receptors, offering potential heart-safe microdose-enabling properties for mental health disorders.

What makes MYCO-005 unique?

MYCO-005 is engineered to reduce side effects and address valvular fibrosis concerns associated with traditional psilocin analogs, providing a safer alternative for anxiety or depression disorders.

What is Mydecine Innovations Group's focus?

Mydecine Innovations Group Inc. is dedicated to revolutionizing mental health and addiction treatment through innovative biotechnological advancements and research in the field.

How does Mydecine support the farming industry?

Mydecine provides turnkey growing infrastructure and services for licensed growers and processors of marijuana crops, showcasing a commitment to advancing agriculture and biotechnological solutions.

Who leads the scientific efforts at Mydecine?

Rob Roscow, Chief Scientific Officer at Mydecine, highlights the research on MYCO-005 and its potential as a safer alternative for microdosing in mental health disorders.

What patent has Mydecine received recently?

Mydecine received a Notice of Allowance from the USPTO for their MYCO-005 compound, emphasizing their commitment to innovation in mental health therapeutics.

What safety features does MYCO-005 offer?

MYCO-005 selectively binds to 5-HT2A receptors while avoiding binding to 5-HT2B receptors, suggesting an enhanced safety profile for microdosing and reducing cardiovascular risks.

Why is MYCO-005 considered a breakthrough compound?

MYCO-005 addresses stability and receptor binding concerns associated with first-generation psilocin analogs, introducing a novel compound with heart-safe microdose-enabling properties.

How does Mydecine contribute to mental health research?

Mydecine Innovations Group continues to pioneer safer and more effective solutions for mental health and addiction disorders, showcasing a dedication to biotechnological advancements and innovative therapies.

What sets Mydecine apart in the biotechnology field?

Mydecine's commitment to innovation, research, and dedication to advancing mental health and addiction treatments through breakthrough compounds like MYCO-005 sets them apart in the biotechnology industry.